Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.

ABSTRACT:

Objective

To develop a population pharmacokinetic model for lopinavir boosted by ritonavir in coronavirus disease 2019 (Covid-19) patients.

Methods

Concentrations of lopinavir/ritonavir were assayed by an accredited LC-MS/MS method. The population pharmacokinetics of lopinavir was described using non-linear mixed-effects modeling (NONMEM version 7.4). After determination of the base model that better described the data set, the influence of covariates (age, body weight, height, body mass index (BMI), gender, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), C reactive protein (CRP), and trough ritonavir concentrations) was tested on the model.

Results

From 13 hospitalized patients (4 females, 9 males, age = 64 ± 16 years), 70 lopinavir/rito

SUBMITTER: Alvarez JC 

PROVIDER: S-EPMC7552959 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature